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ABSTRACT:
Multiple myeloma (MM) is a B cell malignancy characterized by clonal proliferation 
of plasma cells in the bone marrow. With the advent of novel targeted agents, the 
median survival rate has increased to 5 -7 years. However, majority of patients with 
myeloma suffer relapse or develop chemoresistance to existing therapeutic agents. 
Thus, there is a need to develop novel alternative therapies for the treatment of 
MM. Thus in the present study, we investigated whether thymoquinone (TQ), a 
bioactive constituent of black seed oil, could suppress the proliferation and induce 
chemosensitization in human myeloma cells and xenograft mouse model. Our results 
show that TQ inhibited the proliferation of MM cells irrespective of their sensitivity 
to doxorubicin, melphalan or bortezomib. Interestingly, TQ treatment also resulted 
in a significant inhibition in the proliferation of CD138+ cells isolated from MM 
patient samples in a concentration dependent manner. TQ also potentiated the 
apoptotic effects of bortezomib in various MM cell lines through the activation of 
caspase-3, resulting in the cleavage of PARP. TQ treatment also inhibited chemotaxis 
and invasion induced by CXCL12 in MM cells. Furthermore, in a xenograft mouse 
model, TQ potentiated the antitumor effects of bortezomib (p < 0.05, vehicle versus 
bortezomib + TQ; p < 0.05, bortezomib versus bortezomib + TQ), and this correlated 
with modulation of various markers for survival and angiogenesis, such as Ki-67, 
vascular endothelial growth factor (VEGF), Bcl-2 and p65 expression. Overall, our 
results demonstrate that TQ can enhance the anticancer activity of bortezomib in vitro 
and in vivo and may have a substantial potential in the treatment of MM.
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INTRODUCTION
Cancer is a major public health problem worldwide. 
According to World Cancer Research Fund International, 
there were an estimated 12.7 million cancer deaths (13% 
of all deaths) worldwide in 2008, males accounting for 
6.6 million and females accounting for 6 million. Multiple 
myeloma (MM) is a B cell malignancy involving the 
post germinal center B cells. The disease is characterized 
by clonal proliferation and accumulation of terminally 
differentiated plasma cells that produce immunoglobulin 
[1], presence of blood and urinary monoclonal proteins, 
osteolytic bone lesions, infiltration of bone marrow with 
malignant plasma cells [2]. Generally, MM is preceded 
by two premalignant conditions namely monoclonal 
gammopathy of undetermined significance (MGUS) and 
smoldering (asymptomatic) multiple myeloma (SMM) 
[3, 4]. MM is the second most common hematological 
malignancy next only to non-Hodgkin’s lymphoma, 
contributing 13% of all malignancies and 1% of all 
neoplasias [5]. 
Common front line agents used in the induction 
therapy of MM are either two drug or three drug 
combinations of melphalan, dexamethasone, thalidomide, 
lenalidomide and bortezomib [6]. Bortezomib, a novel 
dipeptide boronate, was the first therapeutic proteasome 
inhibitor to be tested in humans. The regimens available 
for the treatment of relapsed and refractory MM are 
carfilzomib, bortezomib, thalidomide-dexamethasone and 
lenalidomide-bendamustine-dexamethasone combination 
[7]. Pomalidomide, a third generation immunomodulatory 
agent has also been recently approved by the FDA for 
the treatment of relapsed and refractory MM [8]. The 
introduction of novel drugs that target specific intracellular 
pathways and affect cellular interactions within the 
tumor microenvironment, have significantly aided in the 
clinical management of MM patients. However, MM still 
remains incurable as majority of the patients suffer from 
relapse after initial response or develop chemoresistance. 
Moreover, most of the available drugs have severe dose-
limiting toxicity including but not limited to bone marrow 
suppression, peripheral neuropathy, and reactivation of 
herpes zoster infection [9]. Thus, there remains an unmet 
need to develop novel therapies for MM treatment.
Resistance to chemotherapy remains a major 
therapeutic challenge in MM. Several biological 
mechanisms are implicated in chemoresistance, including 
multidrug resistance (MDR1/P-glycoprotein [P-gp] 
or p170), resistance-related proteins (p95 and p110), 
multidrug resistance-associated protein (p190), proteins 
implicated in cell detoxification such as glutathione 
S-transferase and genes affecting DNA structure 
(topoisomerases) [10]. The precise mechanism underlying 
chemoresistance in MM is not clear, but one of the main 
contributors to both chemoresistance and pathogenesis 
is thought to be activation of master transcription factor 
NF-κB and dysregulation of apoptosis [11, 12]. Many 
studies have shown that the NF-κB signaling pathway 
plays an important role in anti-apoptosis and the drug 
resistance of tumor cells during chemotherapy. First, many 
chemotherapeutic drugs and radiotherapy induce NF-κB 
expression in vitro and in vivo [12, 13]. Second, activation 
of NF-κB rescues cells from chemotherapy induced 
apoptosis [14]. Third, induction of chemoresistance and 
radioresistance is mediated via genes regulated by NF-κB 
[12]. Fourth, inhibition of NF-κB and NF-κB regulated 
gene products increases the sensitivity of cancer cells to 
apoptosis induced by chemotherapeutic agents and to 
radiation exposure [12, 15]. Activation of NF-κB in MM 
cells induces proliferation, survival and chemoresistance. 
When compared to chemosensitive MM cell lines 
chemoresistant MM cells express higher levels of NF-κB, 
suggesting a link between NF-κB and development of 
chemoresistance [15]. Thus targeting deregulated NF-κB 
activation can be an important strategy pharmacological 
strategy to overcome chemoresistance in MM patients.
Hence, in the present study we investigated whether 
thymoquinone (2-isopropyl-5- methyl-1,4-benzoquinone, 
TQ) can significantly augment the apoptotic effects 
of bortezomib, both under in vitro system and in vivo 
conditions using human MM cells and xenograft mouse 
model. We focused specifically on TQ as it has been 
shown to possess anti-inflammatory, antioxidant, anti-
hypertensive and anti-neoplastic effects in various tumor 
cells including MM through the modulation of diverse 
oncogenic molecular targets [12, 16-18]. We report 
for the first time that TQ inhibited the growth of MM 
U266 tumors in a subcutaneous mouse model, and that 
combination of TQ with bortezomib further inhibited 
tumor growth through the modulation of various markers 
of proliferation, survival and angiogenesis.
RESULTS
In this study we investigated whether TQ can 
sensitize MM cells to bortezomib, a clinically used 
proteasome inhibitor, and the underlying molecular 
mechanisms involved. To determine the tumor growth 
inhibition under in vivo conditions, we used a xenograft 
mouse model. The structure of TQ is shown in Fig. 1A.
Anti-proliferative effects of TQ on human MM 
cell lines and patient samples
Anti-myeloma effect of TQ was evaluated by 
assessing the cell viability of different MM cell lines 
resistant to various pharmacological drugs. Specifically, 
we investigated the effect of TQ on RPMI-8226, RPMI-
8226-Dox6 (resistant to doxorubicin), RPMI 8226-LR5 
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(resistant to melphalan), and RPMI-8226-BR (bortezomib 
resistant) using MTT assay. The data obtained indicated 
that TQ can significantly suppress the proliferation of all 
MM cell types examined in a dose- and time-dependent 
manner (Fig. 1B). We next investigated the effect of TQ 
on the proliferation of CD138+ cells from 5 patients with 
MM. The cells were exposed to different concentrations of 
TQ and then examined for cell proliferation by the MTT 
method. As shown in Fig. 1C, exposure of CD138+ cells 
from all 5 MM patients to TQ decreased cell proliferation 
in a dose-dependent manner.
TQ potentiates the apoptotic effect of bortezomib 
in MM cells
Bortezomib, an inhibitor of proteasome have been 
approved for the treatment of patients with MM [15]. 
We examined whether TQ can potentiate the apoptotic 
effect of bortezomib in U266 cells. For this, U266 cells 
were treated with TQ (5 μM), bortezomib (20 nM) and 
a combination of both, and then examined for apoptosis 
using cell cycle analysis and annexin V staining by flow 
cytometry. We found that treatment with a combination of 
TQ and bortezomib caused statistically significant increase 
in the accumulation of cell population in the sub-G1 phase 
as compared to U266 cells treated with TQ or bortezomib 
alone (Fig. 2A). To further confirm this observation, 
we used annexin V staining assay, which detects an 
early stage of apoptosis. The findings of this assay also 
indicated an enhancement in the apoptotic effects of 
bortezomib by TQ (Fig. 2B). Cleavage of procaspase-3 to 
caspase-3 and caspase-3–mediated cleavage of PARP are 
major characteristic features of apoptosis. In U266 cells 
treated with a combination of TQ and bortezomib, there 
was a substantial activation of the effector molecule pro-
caspase-3, with a concomitant increase in cleaved form 
of caspase-3 (Fig. 2C). Moreover, activation of caspase-3 
led to the cleavage of a 118 kDa Poly (ADP-ribose) 
polymerase (PARP) protein into an 85 kDa fragment (Fig. 
2D). These results clearly suggested that TQ can augment 
the apoptotic effect of bortezomib through the activation 
of caspase-3 in MM cells.
We also analyzed whether TQ can enhance the 
apoptotic effect of bortezomib in three other MM cell 
lines namely, H929, KMS-11 and RPIMI 8226. We found 
that treatment with TQ in combination with bortezomib 
substantially increased the PARP cleavage in these 
three cell lines (Figs 3A-C). We also found that TQ in 
combination with bortezomib caused significant increase 
Fig 1: TQ suppresses the proliferation of MM cell lines. A, Chemical structure of TQ. B, doxorubicin-sensitive and doxorubicin-
resistant RPMI 8266 cells, melphalan-sensitive and melphalan-resistant RPMI 8266 cells, and  bortezomib-sensitive and bortezomib-
resistant RPMI 8266 cells were plated in triplicate, treated with different concentrations of TQ for 24 , 48 and 72 h, and then subjected to 
MTT assay to analyze proliferation of cells. Each point on line is an average of triplicate value. C, CD138+ cells were isolated from MM 
patient samples as described in Materials and Methods. The cells were plated in triplicate, treated with different concentrations of TQ and 
then subjected to MTT assay to analyze proliferation of cells. Columns, mean; bars, SD. *, p < 0.05.
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in the cell population in sub-G1 phase as compared to the 
MM cells treated with TQ or bortezomib alone (Figs. 3D-
F). these findings clearly indicate the potential of TQ to 
augment the apoptotic effects of bortezomib in diverse 
MM cell lines.
Fig 2: TQ potentiates the apoptotic effect of bortezomib 
causing accumulation of U266 cells in sub-G1 phase, 
activates caspase-3 and induce PARP cleavage. A, U266 
cells were synchronized by serum starvation and then exposed to 
TQ (5 μM), bortezomib (20 nM) and a combination of both for 
24 h at 37°C. The cells were then washed, fixed, stained with PI, 
and analyzed for DNA content by flow cytometry. B, U266 cells 
were synchronized by serum starvation and then exposed to TQ 
(5 μM), bortezomib (20 nM) and a combination of both for 24 h. 
Cells were incubated with anti-Annexin V antibody conjugated 
with FITC, followed by PI and then analyzed with a flow 
cytometry to detect early apoptotic effects. C, U266 cells were 
treated with TQ (5 μM), bortezomib (20 nM) and a combination 
of both for 24 h at 37°C. Whole-cell extracts were prepared, 
separated on SDS-PAGE, and subjected to Western blot analysis 
using antibody against procaspase-3 and cleaved caspase-3. The 
same blots were stripped and reprobed with β-actin antibody to 
show equal protein loading. D, U266 cells were treated with TQ 
(5 μM), bortezomib (20 nM) and a combination of both for 24 h 
at 37°C. Whole-cell extracts were prepared, separated on SDS-
PAGE, and subjected to Western blot analysis using antibody 
against PARP. The same blots were stripped and reprobed with 
β-actin antibody to show equal protein loading. Results typical 
of two independent experiments are shown.
Fig 3: TQ potentiates the apoptotic effect of bortezomib 
in various MM cell lines. A, H929 cells were treated with 
TQ (5 μM), bortezomib (20 nM) and a combination of both 
for 24 h at 37°C. Whole-cell extracts were prepared, separated 
on SDS-PAGE, and subjected to Western blot analysis using 
antibody against PARP. The same blots were stripped and 
reprobed with β-actin antibody to show equal protein loading. 
B, KMS-11 cells were treated with TQ (5 μM), bortezomib (20 
nM) and a combination of both for 24 h at 37°C. Whole-cell 
extracts were prepared, separated on SDS-PAGE, and subjected 
to Western blot analysis using antibody against PARP. The same 
blots were stripped and reprobed with β-actin antibody to show 
equal protein loading. C, RPMI 8226 cells were treated with TQ 
(5 μM), bortezomib (20 nM) and a combination of both for 24 h 
at 37°C. Whole-cell extracts were prepared, separated on SDS-
PAGE, and subjected to Western blot analysis using antibody 
against PARP. The same blots were stripped and reprobed with 
β-actin antibody to show equal protein loading. D, H929 cells 
were synchronized by serum starvation and then exposed to TQ 
(5 μM), bortezomib (20 nM) and a combination of both for 24 h 
at 37°C. The cells were then washed, fixed, stained with PI, and 
analyzed for DNA content by flow cytometry. E, KMS-11 cells 
were synchronized by serum starvation and then exposed to TQ 
(5 μM), bortezomib (20 nM) and a combination of both for 24 
h at 37°C. The cells were then washed, fixed, stained with PI, 
and analyzed for DNA content by flow cytometry. F, RPMI 8226 
cells were synchronized by serum starvation and then exposed 
to TQ (5 μM), bortezomib (20 nM) and a combination of both 
for 24 h at 37°C. The cells were then washed, fixed, stained with 
PI, and analyzed for DNA content by flow cytometry. Results 
typical of two independent experiments are shown.
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TQ suppresses MM cell migration and invasion
The effect of TQ on migration and invasion of U266 
cells was also investigated. The addition of TQ to the 
media with U266 cells in the top chambers of transwell 
inserts significantly reduced the migration of the cells 
into the bottom chamber containing CXCL12, a potent 
lymphocyte chemotactic factor (Fig. 4A). Using an in vitro 
invasion assay, we also found that CXCL12 significantly 
induced the invasion of U266 cells across the matrigel 
coated polycarbonate membrane and that treatment with 
TQ significantly abrogated the invasive activity (Fig. 4B).
TQ downregulates the expression of CXCR4, 
COX-2 and MMP-9 proteins in MM cells
Treatment of U266 cells with TQ was found to 
downregulate the expression of the chemokine receptor 
CXCR4, which is specific for CXCL12, the mediator of 
inflammation, COX-2 and key matrix metalloproteinase 
MMP-9, which is involved in breakdown of cellular matrix 
and initiation on invasion. Their expression decreased in 
a time-dependent manner, with maximum suppression 
observed at around 48 h (Fig. 4C). The downmodulation in 
the expression of these proteins may account for observed 
anti-migratory and anti-invasive potential of TQ.
Fig 4: TQ inhibits migration and invasion of MM cell 
lines. A, U266 cells (50x104/well) were plated in 0.3 ml cell 
culture media with and without 15 μM TQ in the top chambers 
of 24-well transwell inserts with 8-mm pores. Cell culture 
medium (600 μl) containing the recombinant human B-cell 
chemoattractant, CXCL12 (SDF-1α) was added to the bottom 
chamber and incubated for 12 hours. After incubation, the insert 
was removed and calcein-AM (5 μM) was added to the wells 
and fluorescence was measured. Columns, mean; bars, SD. *, 
p < 0.05. B, U266 cells (50 x104) in suspension were starved 
in serum-free RPMI-1640 for 3 h, and then loaded onto the 
Matrigel-coated inserts in the upper chambers of tissue culture 
inserts placed in 24 well plates. The wells of the plate were filled 
with 600-μl of 10% FBS-containing cell culture media with 100 
ng/ml CXCL12 (SDF-1α). TQ (15 μM) was added with the cells 
to the upper chamber. Plates were then incubated at 37°C for 
12 h. At the end of the incubation period, calcein-AM (5 μM) 
was added to the wells containing invasive cells, incubated 
at 37°C for 1 hour and fluorescence was measured. Columns, 
mean; bars, SD. *, p < 0.05. C, U266 cells were treated with 
TQ (15 μM) for 0, 12, 24, 36 and 48 h at 37°C. Whole-cell 
extracts were prepared, separated on SDS-PAGE, and subjected 
to Western blot analysis using antibody against CXCR4, COX-2 
and MMP-9. The same blots were stripped and reprobed with 
β-actin antibody to show equal protein loading.
Fig 5: TQ potentiates the anti-tumor activity of 
bortezomib in xenograft mouse model. A, schematic 
representation of experimental protocol as described in 
Materials and Methods. Group I was given 0.1% DMSO (100 
μL, i.p., daily), group II was given bortezomib (0.25 mg/kg body 
weight, i.p., once in a week], group III was given TQ (1 mg/kg 
body weight, i.p., daily), and group IV was given bortezomib 
(0.25 mg/kg body weight, i.p., once in a week) and TQ (1 mg/
kg body weight, i.p., daily) for 4 weeks. B, photographs of 
tumor tissue dissected from the mice after the end of treatment 
period. C, tumor volumes in mice measured on the last day of 
the experiment with Vernier calipers and calculated using the 
formula V= 4/3πr3 (n= 6). Columns, mean; bars, SD. *, p < 0.05. 
D, tumor volumes measured during the course of experiment and 
calculated using the formula V= 4/3πr3, *, p < 0.05.
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TQ potentiates the antitumor effects of 
bortezomib in a xenograft MM mouse model
We next examined the therapeutic potential of 
TQ and bortezomib either alone or in combination on 
the growth of subcutaneously implanted U266 cells in 
nude mice. The detailed procedures used to establish 
the U266 model in the athymic nude mice and to treat 
the mice with TQ, bortezomib, and the combination of 
TQ and bortezomib is depicted in Fig. 5A. The average 
tumor volume in bortezomib alone and TQ alone treated 
groups was significantly smaller than untreated animals 
(49% and 45%, respectively) as soon as day 15, while at 
day 30, the average tumor volumes of the bortezomib-
alone and the TQ alone treated group were 58% and 47% 
less than that of the untreated control, respectively. The 
average tumor volume in bortezomib + TQ -treated group 
was significantly less (60% at day 15 and 72% at day 30) 
than in the untreated group (P<0.05) and the bortezomib 
alone treated group (P<0.05), from day 15 through day 30. 
Overall, these findings indicated that the combination of 
bortezomib and TQ was significantly effective in reducing 
the tumor burden in treated mice (Figs. 5B-D).
Fig 6: TQ enhances the effect of bortezomib against the expression of NF-κB and inhibit proliferation in MM tumor. A, 
detection of NF-κB activation by DNA-binding assay in tumor tissue samples. Tumor tissues from animals were processed and used for DNA 
binding assay (Active Motiff) as described in Materials and Methods. The results showed a significant inhibition of NF-κB DNA binding 
in mice treated with TQ in combination with bortezomib. Columns, mean; bars, SD; *, p < 0.05. B, Western blot analysis using whole-
cell extracts from tumor tissue showed the inhibition of NF-κB (p65) by TQ in combination with bortezomib. C, immunohistochemical 
analysis of NF-κB p65 expression in mice treated with TQ either alone or in combination with bortezomib. Right, quantification of NF-κB 
p65 positive cells as described in Materials and Methods. Columns, mean; bars, SD; *, p< 0.05. D, left, immunohistochemical analysis of 
proliferation marker Ki-67 indicates the inhibition of U266 cell proliferation in TQ either alone or in combination with bortezomib treated 
groups of mice. Right, quantification of Ki-67 positive cells as described in Materials and Methods. Columns, mean; bars, SD; *, p< 0.05.
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TQ inhibits NF-κB DNA binding activity and 
the constitutive NF-κB expression in MM tumor 
tissues
The pro-inflammatory transcription factor NF-κB 
plays a pivotal role in the proliferation and survival of 
various kinds of B-cell tumors, including MM [19, 20]; 
therefore, the levels of constitutive NF-κB activation in 
MM tumor tissues was next examined by ELISA-based 
TransAM NF-κB assay kit. The DNA-binding assay for 
NF-κB in nuclear extracts from tumor samples showed 
that TQ in combination with bortezomib significantly 
suppressed NF-κB activation, while TQ alone and 
bortezomib alone had much lesser inhibition on NF-κB 
than the drug combination (Fig. 6A). We also evaluated the 
effect of TQ and bortezomib on NF-κB (p65) activation 
by western blot analysis of whole cell extract obtained 
from MM tissues. Our results clearly showed that the 
phosphorylation of NF-κB (p65) subunit was substantially 
reduced in extracts from tumor samples of mice treated 
with a combination of TQ and bortezomib (Fig. 6B).
TQ inhibits NF-κB (p65) and Ki-67 expression in 
MM tumor tissues
NF-κB is known to regulate the expression of 
numerous genes involved in MM pathogenesis, including 
growth, survival, immortalization, angiogenesis and 
metastasis [20, 21], while the nuclear protein Ki-67 is a 
proliferation index, as it is expressed only by dividing 
cells. The nuclear localization of p65 and the expression 
of Ki-67 was examined using an immunohistochemical 
method described previously [22]. Whether TQ and 
bortezomib can modulate these markers in MM tumor 
Fig 7: TQ enhances the effect of bortezomib against MM tumor cell proliferation. A, immunohistochemical analysis of the 
pro-angiogenic growth factor VEGF expression in mice treated with TQ either alone or in combination with bortezomib. Right, quantification 
of VEGF positive cells as described in Materials and Methods. Columns, mean; bars, SD; *, p < 0.05. B, immunohistochemical analysis 
of the survival protein Bcl-2 expression in mice treated with TQ either alone or in combination with bortezomib. Right, quantification of 
Bcl-2 positive cells as described in Materials and Methods. Columns, mean; bars, SD; *, p < 0.05. C, immunohistochemical analysis of 
caspase-3 expression in mice treated with TQ either alone or in combination with bortezomib. Right, quantification of caspase-3 positive 
cells as described in Materials and Methods. Columns, mean; bars, SD; *, p < 0.05
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tissues was examined. We found that both agents 
significantly reduced the p65 expression as compared 
with control group individually and the combination was 
most effective (p < 0.05 when compared with TQ alone; 
Fig. 6C). Fig. 6D shows that both TQ (p < 0.05) and 
bortezomib (p < 0.05) alone significantly downregulated 
the expression of Ki-67 in MM tumor tissues and the 
combination of the two was even more effective (p < 
0.05).
TQ inhibits expression of VEGF and Bcl-2 in 
tumor tissues
VEGF, another protein regulated by NF-κB plays an 
important role in angiogenesis and growth of MM cells, so 
we next examined its expression in MM tumor samples. 
Our results showed that TQ alone and bortezomib alone 
significantly decreased the expression of VEGF in tumor 
tissue (Fig. 7A). However, TQ + bortezomib combination 
was more effective in reducing VEGF expression than 
either agent used alone (p < 0.05 versus TQ alone). 
The Bcl-2 protein, regulated by NF-κB is also highly 
expressed in myeloma patients and in vitro studies have 
shown its role in the regulation of chemosensitivity [23, 
24]. As shown in Fig. 7B, the expression of Bcl-2 in MM 
tumor tissue was significantly downregulated in mice 
treated with either TQ or bortezomib alone. However, the 
downregulation was more substantial in mice treated with 
a combination of TQ and bortezomib. Next, to determine 
whether TQ decreases MM tumor growth by inducing 
apoptosis, we examined the caspase-3-positive cells in 
tumors obtained from mice. Our results showed that TQ 
alone and bortezomib alone caused a similar level of 
increase in caspase-3 expression. Interestingly, we found 
that the TQ + bortezomib combination was substantially 
more effective in inducing caspase-3 activation rather than 
either agent used alone (Fig. 7C; p< 0.05 versus vehicle 
and TQ alone).
TQ reduces serum levels of IL-6 and TNF- α in 
MM tumor bearing mice
The pro-inflammatory cytokines IL-6 and TNF-α, 
are considered as major biomarkers of inflammation. 
Hence, we also analyzed the effect of TQ and bortezomib 
on the levels of these two cytokines in serum samples 
obtained from mice. MM tumor-bearing mice treated 
with TQ and bortezomib alone or in combination were 
sacrificed at the end of each treatment protocol. Blood 
was collected via cardiac puncture and serum separated 
and used to evaluate the levels of IL-6 and TNF-α using 
an ELISA kit. Interestingly, levels of both IL-6 and TNF-α 
level was found to be substantially higher in untreated 
tumor bearing mice. TQ and bortezomib alone treatment 
significantly decreased serum IL-6 when compared to 
control, while the TQ + bortezomib treated mice had 77% 
reduction in serum IL-6 compared to untreated control (p 
< 0.05) (Fig.8A). Similarly serum levels of TNF-α was 
significantly reduced in mice treated with a combination 
of TQ and bortezomib (61%, p < 0.05 versus untreated 
control) (Fig.8B).  
DISCUSSION
The aim of this study was to determine whether 
TQ could augment the apoptotic effect of bortezomib 
in MM cell lines and xenograft mouse model and if so 
through what mechanisms. We found that TQ inhibited the 
proliferation of various MM cell lines regardless of their 
sensitivity/resistance to the conventional chemotherapeutic 
agents such as doxorubicin, melphalan and/or targeted 
therapies such as bortezomib. TQ also inhibited the 
survival of CD138+ plasma cells obtained from MM 
patients in a dose dependent manner. It potentiated the 
apoptotic effects of bortezomib in MM cells as evidenced 
by increased accumulation of cells in the sub-G1 phase 
Fig 8: TQ modulates serum levels of IL-6 and TNF-α 
in MM tumor bearing mice. A, All four groups of mice 
were treated as described in Materials and Methods. Sandwich 
ELISA assay was performed as per manufacturers’ instruction 
R&D systems (Minneapolis, USA) to determine the levels of 
IL-6. *Statistical significance (p < 0.05). B, All four groups of 
mice treated as described in Materials and Methods. Sandwich 
ELISA assay was performed as per manufacturers’ instruction 
R&D systems (Minneapolis, USA) to determine the levels of 
TNF-α. *Statistical significance (p < 0.05).
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leading to the caspase-3 activation and PARP cleavage. 
Our results also show that enhancement of apoptotic 
effects of bortezomib induced by TQ is not limited to one 
MM cell line, but can be observed in several MM cell 
lines. We further observed that in a xenograft mouse model 
TQ alone and in combination with bortezomib effectively 
suppressed the growth of subcutaneous tumor of MM 
cells through the suppression of NF-κB activation. This 
correlated with down-regulation of various proliferative, 
anti-apoptotic, angiogenic and inflammatory biomarkers 
regulated by NF-κB in MM tumor tissues.
The pathogenesis of MM involves characteristic 
genetic abnormalities and the interaction between 
the clonal plasma cells and the bone marrow 
microenvironment [25]. Unlike other hematological 
malignancies and similar to solid tumors, the genetic 
abnormalities of MM are heterogeneous and the 
transformation is not driven by a single gene mutation. 
Thus developed MM, through complex genetic and 
epigenetic events further progresses and is no longer 
dependent on bone marrow microenvironment for survival 
leading to extramedullary MM. Adhesion of MM cells to 
the stromal cells induces the latter to secrete IL-6. IL-6 
is the main growth factor for the MM cells. In turn IL-6 
then induces janus kinase (JAK) / signal transducer 
and activator of transcription 3 (STAT3), PI3K/Akt and 
mitogen-activated protein kinase survival pathways in 
MM cells [20, 26]. We had previously reported that TQ 
can indeed inhibit proliferation and induce apoptosis in 
MM cells through the suppression of signal transducer and 
activator of transcription 3 (STAT3) activation pathway 
[12]. However, the effect of TQ on drug resistant MM 
cell lines, patient samples and xenograft mouse model 
was not investigated in that report. Moreover, we have 
also reported NF-κB inhibitory potential of TQ in diverse 
tumor cell lines previously [17], which may account for its 
observed anti-proliferative/apoptotic effects as observed in 
the present study. 
CXCL12 is a member of CXC family of cytokines 
and its cognate receptor is CXCR4. It has been implicated 
in progression, migration, invasion and metastasis of 
various cancers [27]. BMSCs secrete this chemokine, 
with the MM cells from the patient sample and MM 
derived cell lines expressing the cognate receptors [28]. 
This chemokine mediates the secretion of IL-6 and 
VEGF and induces proliferation, migration and inhibits 
dexamethasone induced cell death [29]. Accordingly, 
CXCL12 induces invasion and CXCR4 antagonists 
can negatively regulate CXCL12-induced invasion. 
We noted that TQ can significantly inhibit CXCL12 
induced chemotactic movement as well as invasive 
potential in MM cell lines which may be mediated by the 
downregulation of CXCR4 expression as observed by 
western blot analysis.
MMPs belong to a family of proteases, capable of 
degrading all kinds of extracellular matrix proteins [30]. 
Culture supernatants of bone marrow derived stromal cells 
from MM patients have been found to have higher levels 
of MMP than control samples [31]. Moreover, endothelial 
cells can secrete hepatocyte growth factor, which then acts 
on MM cells to stimulate the secretion of MMP-9 [32]. 
Adequate inhibition of various MMPs by a broad spectrum 
MMP inhibitor SC-964 can suppress angiogenesis, 
reduces tumor load and osteolytic lesions [33]. Our study 
showed that TQ could substantially inhibit the expression 
of MMP-9 in MM cell lines, which may account for its 
observed anti-migratory/anti-invasive effects in MM cells.
In the present study, we also investigated for the first 
time the potential effect of TQ alone or in combination 
with bortezomib on MM growth in a xenograft mouse 
model. We found that the intraperitoneal administration 
of TQ alone could inhibit the growth of MM tumors in the 
xenograft model. Bortezomib also induced a significant 
inhibition of tumor growth. But when the two agents 
were used in combination, they were found to be much 
more effective in significantly suppressing the growth 
of MM tumor. When examined for the mechanisms, 
we observed that the activation of transcription factor 
NF-κB was substantially attenuated by these two drugs 
when used in combination. NF-κB has been casually 
implicated in progression of various types of tumors 
[14]. MM patient samples show a constitutive activation 
of NF-κB to variable degree. 15-20% of MM samples 
and 40% of the cell lines show mutations that lead to 
constitutive activation of NF-κB pathway [34]. Activation 
of NF-κB in MM cells induces proliferation, survival 
and chemoresistance. When compared to chemosensitive 
MM cell lines chemoresistant MM cells express higher 
levels of NF-κB, suggesting a link between NF-κB and 
development of chemoresistance [12, 35]. Moreover, 
dexamethasone induced apoptosis is associated with 
a decrease in the NF-κB DNA binding activity [35]. In 
agreement with these previous reports, we also found that 
MM tumor samples had elevated levels of basal NF-κB 
expression as well as increased activation as observed by 
DNA binding and western blot analysis. Previous studies 
has shown that NF-κB activation was inhibited when 
bortezomib was added, suggesting that bortezomib can 
sensitize MM cells to alkylating agents by inhibiting NF-
κB activation [36]. In our study we found that bortezomib 
can decrease the NF-κB activation in MM tumor samples, 
but the TQ combination had a significant inhibition in NF-
κB activation even when compared to bortezomib alone 
treatment. This may explain the chemosensitizing effects 
of TQ as observed here and also reported previously [12, 
17].
VEGF is an important signaling protein regulated 
by NF-κB that stimulates the formation of new blood 
vessels, through vasculogenesis and angiogenesis [37]. 
Dysregulation of VEGF has been shown to be a major 
contributor to tumor angiogenesis as well, promoting 
tumor growth, invasion and metastasis [38]. Significantly 
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elevated levels of VEGF are observed in a variety of 
hematological malignancies [39, 40]. VEGF protein 
was found in malignant cells from 75% of MM patients 
studied [41] and increased serum levels of VEGF have 
been correlated with a poor prognosis in patients with 
advanced stages of MM [20, 42]. Thus the observed 
significant downregulation of VEGF expressed in the 
tumor tissues from mice treated with a combination of TQ 
and bortezomib may contribute to the anti-tumor activity 
through the inhibition of angiogenic pathways that are 
essential for the tumor growth. 
Overexpression of anti-apoptotic molecules of Bcl-
2 family has been linked to chemoresistance in MM [20, 
24]. Prior studies has shown that the activation of NF-κB 
can enforce the ectopic expression of Bcl-2 in MM cells 
conferring resistance to dexamethasone induced apoptosis 
through activation of survival pathways [43]. However TQ 
in combination with bortezomib was found to suppress 
the expression of Bcl-2 in MM tissues, which may also 
account for its tumor inhibitory effects. This decline in 
the survival signaling pathway contributed to the increased 
apoptosis in the tumor tissues as evidenced by increase in 
caspase-3 expression by immunohisrochemistry. IL-6, a 
pleiotropic cytokine, is one of the major growth factors 
in MM [44]. IL-6 induces survival of MM cell through 
activation of STAT3, which upregulates anti-apoptotic 
proteins Bcl-xL and Mcl-1 and cell cycle proteins like 
cyclin D1, and cyclin E [20, 24]. The fact that TQ can 
abrogate IL-6 induced STAT3 activation has already been 
reported by our group previously [12]. In the present 
study, we noted that MM bearing mice treated with TQ 
in combination with bortezomib produced a significant 
inhibition in the production of IL-6, when compared to 
both vehicle control and bortezomib alone treated groups, 
indicating that the combination is quite effective in 
blocking the IL-6 mediated growth and survival of MM. 
TNF-α is another important growth factor secreted from 
MM cells to act on BMSCs to stimulate the secretion 
of IL-6. TNF-α induces the expression of adhesion 
molecules on both MM cells and BMSCs [45]. TNF-α 
have been reported to be involved in the control of VEGF 
production by MM cells [46]. TNF-α also participates 
in transendothelial migration of MM cells by acting 
via TNF-R2 and upregulating the secretion of MCP-
1 (monocyte chemoattractant protein-1) in MM cells 
[47]. Interestingly, TNF-α blockers such as thalidomide 
and other immunomodulatory agents have exhibited 
significant anti-myeloma activity [48]. We observed that 
TQ in combination with bortezomib produced significant 
reduction in the serum levels of TNF-α, which can 
contribute to the anti-tumor activity. Also since both these 
cytokines are regulated by NF-κB, inhibitory effects of TQ 
on NF-κB may explain its potential suppressive effects on 
the serum levels of IL-6 and TNF-α. 
TQ has been extensively studied so far in diverse 
tumor models without exhibiting any significant toxic 
effects to normal cells [16]. However, TQ has never been 
tested in humans before either alone or in combination 
with targeted therapies and hence its clinically relevant 
doses are not clear as yet. Overall, the ability of TQ 
to inhibit cell proliferation, migration, invasion and 
potentiate the apoptotic effects of bortezomib while 
suppressing NF-κB activation and its regulated gene 
products, provides a sound rationale to test this agent to 
enhance treatment efficacy, reduce toxicity, and overcome 
chemoresistance of relapsed or refractory MM.
MATERIALS AND METHODS
Reagents
Thymoquinone, MTT, Tris, glycine, NaCl, SDS, 
BSA and β-actin antibody were obtained from Sigma-
Aldrich (Missouri, USA). TQ was dissolved in dimethyl 
sulfoxide (DMSO) as a 50 mM stock solution and stored 
at −20°C for the experiments. Further dilution was done in 
cell culture medium, so that the final DMSO concentration 
was less than 0.1%. RPMI 1640, 0.4% trypan blue vital 
stain and antibiotic-antimycotic mixture were obtained 
from Invitrogen (California, USA). Fetal bovine serum 
(FBS) was purchased from BioWest (Miami, FL, USA). 
Antibodies to p65, COX-2, Bcl-2, Ki-67, VEGF, pro-
caspase-3, cleaved caspase-3, PARP, MMP-9, CXCR4, 
goat anti-rabbit-horse radish peroxidase (HRP) conjugate 
and goat anti-mouse HRP were obtained from Santa 
Cruz Biotechnology (CA, USA). ELISA kits for mouse 
IL-6 and TNF-α were purchased from R&D Systems Inc 
(Minneapolis, USA). Nuclear extraction and DNA binding 
kits was obtained from Active Motif (Carlsbad, CA).  
Cell lines
Human MM cell lines U266, H929, KMS, RPMI-
8226, RPMI-8226-Dox-6 (doxorubicin-resistant clone), 
RPMI-8226-LR-5 (a melphalan-resistant clone) were 
kindly provided by Dr Leif Bergsagel from Mayo Clinic, 
Arizona, USA. RPMI-8226-BR (bortezomib resistant 
clones) was kindly provided by Dr Jacqueline Cloos 
from Vrije Universiteit Medical Center, Amsterdam, 
Netherlands. H929 cells were cultured in RPMI 1640 
medium containing 2-mercaptoethanol at a final 
concentration of 0.05 mM, supplemented with 10% fetal 
bovine serum (FBS). All the other human MM cells were 
cultured in RPMI 1640 supplemented with 10% fetal 
bovine serum (FBS) containing 1 X antibiotic-antimycotic 
solution.
Oncotarget644www.impactjournals.com/oncotarget
Cell proliferation assay 
The anti-proliferative effect of TQ against various 
MM cell lines and patient samples was determined by the 
MTT dye uptake method. Primary MM patient cells were 
obtained from bone marrow aspirates of patients after 
informed consent and with ethical approval from the NUS 
IRB. Peripheral blood mononuclear cells were separated 
with RBC lysis buffer and subsequently CD138+ plasma 
cells were isolated using magnetic cell sorting with CD138 
easysep magnetic nanoparticles (Stemcells Technologies, 
Singapore) according to manufacturer’s instructions. 
Purified CD138+ patient cells were grown in IMDM, 
Glutamax (Gibco, Invitrogen), supplemented with 20% 
fetal bovine serum (FBS), 100 U/mL penicillin and 
100 µg/mL streptomycin, 10ng/mL of IL-6 (Militenyi 
Biotech,Surrey UK) and 100ng/mL of rhIGF-1(R&D 
Systems, Oxford, UK). All cells were grown at 37°C in a 
humidified atmosphere with 5% CO2.  Briefly, the cells (5 
× 103/well) were incubated in triplicate in a 96-well plate 
in the presence or absence of indicated concentrations of 
TQ in a final volume of 0.2 ml for different time intervals 
at 37 °C. Thereafter, 20 μl of MTT solution (5 mg/ml in 
PBS) was added to each well. After a 4-h incubation in 
the dark at 37 °C, 0.1 ml of lysis buffer (20% SDS, 50% 
dimethylformamide) was added and incubated for 2 h at 
37 °C, followed by measurement of optical density at 570 
nm by Tecan plate reader (Durham, NC).
Flow cytometric analysis 
To determine whether TQ can potentiate the 
apoptotic effect of bortezomib, MM cells were first 
synchronized by serum starvation and then exposed to 
TQ (5 μM), bortezomib (20 nM) and a combination 
of both for 24 h. Thereafter cells were washed, fixed 
with 70% ethanol, and incubated for 30 min at 37°C 
with 0.1% RNase A in PBS. Cells were washed again, 
resuspended, and stained with PBS containing 25 μg/mL 
propidium iodide (PI) for 30 min at room temperature. 
Cell distribution across the cell cycle was analyzed with a 
CyAn ADP flow cytometer (Dako Cytomation).
Annexin V assay
The procedure of annexin V-PI staining was carried 
out according to the manufacturer’s protocol (Invitrogen). 
U266 cells (5× 105/mL) were treated with TQ (5 μM), 
bortezomib (20 nM) and a combination of both for 24 
h. After the incubation, the cells were washed with PBS, 
and resuspended in FITC-conjugated annexin V and PI-
containing binding buffer for 15 min in dark. Samples 
were then analyzed immediately by flow cytometer.
Western blot analysis
For detection of proteins, TQ-treated cells were 
harvested and lysed in whole cell lysis buffer (20 mM 
Tris (pH 7.4), 250 mM NaCl, 2 mM EDTA (pH 8.0), 
0.1% Triton X-100, 0.01 mg/ml aprotinin, 0.005 mg/ml 
leupeptin, 0.4 mM PMSF, and 4 mM NaVO4). Lysates 
were then spun at 14,000 rpm for 10 min to remove 
insoluble material and stored at −80°C for later use. 
The protein content in the lysates was measured by Bio-
Rad Protein Assay Dye Reagent Concentrate (Bio-Rad, 
CA) and equal quantity of protein was resolved on a 
10% SDS gel. After electrophoresis, the proteins were 
electrotransferred to a nitrocellulose membrane, blocked 
with 5% nonfat milk, and probed with appropriate 
antibody overnight at 4°C. The blot was washed, 
exposed to HRP-conjugated secondary antibodies for 1 
h, and finally examined by chemiluminescence (ECL; GE 
Healthcare, Buckinghamshire, UK).
Migration assay
U266 cells (50x104/well) were plated in 0.3 ml 
cell culture media with and without 15 μM TQ in the top 
chambers of 24-well transwell inserts with 8-μm pores. 
Cell culture medium (600 μl) containing the Recombinant 
Human B-cell chemoattractant, CXCL12 (SDF-1α) (100 
ng/ml; Prospec, Ness-Ziona, Israel) was added to the 
bottom chamber and incubated for 12 h. After incubation, 
the insert was removed and calcein-AM (5 μM) was added 
to the wells. The cells were incubated at 37°C for 1 hour to 
allow the cells to internalize calcein-AM. The fluorescence 
was measured (485 nm excitation, 520 nm emission). A 
standard curve was generated with cells ranging from 
50000-1000 cells using calcein-AM under same condition 
and cells number calculated from relative fluorescence of 
treated samples.
Invasion assay
An invasion assay was performed with U266 cells in 
24-well plates with polycarbonate membranes (ThinCert 
8-μm pore size tissue culture insert, Greiner Bio-one, NC, 
USA). Briefly the upper chambers were coated with 50-
μl Matrigel (Becton Dickinson, Bedford, MA, USA) in 
advance according to the directions of the manufacturer. 
U266 cells (50 x104) in suspension were starved in 
serum-free RPMI-1640 for 3 h, and then loaded onto 
the Matrigel-coated inserts in the upper chambers. The 
wells of the plate were filled with 600-μl of 10% FBS-
containing cell culture media with 100 ng/ml CXCL12 
(SDF-1α) (Prospec, Ness-Ziona, Israel). TQ (15μM) 
was added with the cells to the upper chamber. Plates 
were then incubated at 37°C for 12 h. At the end of the 
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incubation period, calcein-AM (5μM) was added to the 
wells containing invasive cells. The cells were incubated 
at 37°C for 1 hour to allow the cells to internalize calcein-
AM. The fluorescence was measured (485 nm excitation, 
520 nm emission). A standard curve was generated with 
cells ranging from 50000-1000 cells using calcein-AM 
under same condition and cells number calculated from 
relative fluorescence of treated samples. 
Xenograft tumor model
All the procedures involving animals were reviewed 
and approved by National University of Singapore 
Institutional Animal Care and Use Committee. Five-
week-old athymic nu/nu male Balb/c mice (Biological 
Resource Centre, Biopolis, Singapore) were implanted 
subcutaneously in the right flank with U266 cells (2 × 106 
cells/100 μL of PBS/Matrigel). When tumors have reached 
0.25 cm in diameter, the mice were randomized into the 
following treatment groups (n = 6/group): (i) untreated 
control (DMSO (0.1%; v/v), 100 μL intraperitoneally); 
(ii) bortezomib (0.25 mg/kg of body weight, suspended in 
DMSO (0.1%; v/v), intraperitoneally, weekly once; (iii) 
TQ (1 mg/kg of body weight, suspended in DMSO (0.1%; 
v/v), intraperitoneally, daily); and (iv) TQ (1 mg/kg of 
body weight, daily) + bortezomib (0.25 mg/kg of body 
weight weekly once), intraperitoneally. The treatment 
was continued for 4 weeks, and then the mice were 
maintained without any drug for 5 more days. The body 
weights and tumor sizes were recorded every five days, 
and the tumor size was determined by a Vernier caliper 
measurement. The animals were euthanized at the end of 
the therapy and blood collected by heart puncture. Primary 
tumors were excised and the final tumor volume was 
measured as V= 4/3πr3, where r is the mean radius of the 
3 dimensions (length, width, and depth). Half of the tumor 
tissue was fixed in formalin and embedded in paraffin for 
immunohistochemistry and routine hematoxylin and eosin 
(H&E) staining. A small portion of tumor (75-100 mg/
mouse) was used for nuclear extraction. The remaining 
tumor tissue was snap frozen in liquid nitrogen and stored 
at -80°C.
Preparation of nuclear extract from tumor 
samples
Nuclear extract was prepared from the MM tumor 
tissues using nuclear extraction kit from Active Motiff 
(Carlsbad, CA), according to manufacturer’s protocol. 
Tumor tissue (75-100 mg/mouse) from control and treated 
mice were minced in 0.3 ml ice-cold 1X hypotonic buffer 
supplemented with DTT and detergent and homogenized 
using a Dounce homogenizer, and then centrifuged at 850 
× g at 4°C for 10 min. The supernatant was transferred 
into a pre-chilled microcentrifuge tube and stored for later 
use. The cell pellet was resuspend cells in 500 μL 1X 
hypotonic buffer and incubate for 15 min on ice. Detergent 
(25 μL) was added, vortexed and the centrifuged for 30 
seconds at 14,000 x g in a microcentrifuge pre-cooled at 
4°C. The resulting nuclear pellet was suspended in 50 μL 
complete lysis buffer and incubated on ice for 30 min with 
intermittent mixing. The suspension was then centrifuged 
at 14,000 × g at 4°C for 30 min. The supernatant (nuclear 
extract) was collected and stored at −70°C until use.
NF-κB DNA-binding assay
To determine NF-κB activation in MM tumor 
samples, we conducted DNA-binding assay using 
TransAM NF-κB Kit (Active Motiff), according to the 
manufacturer’s instructions. Briefly, 20 μg of nuclear 
proteins were added into a 96-well plate coated with 
an unlabeled oligonucleotide containing the consensus 
binding site for NF-κB (5′-GGGACTTTCC-3′) and 
incubated for 1 hour. The wells were washed and 
incubated with antibodies against NF-κB p65 subunit 
for 1 hour. An HRP-conjugated secondary antibody 
was then applied to detect the bound primary antibody 
and it provided the basis for colorimetric quantification. 
The enzymatic product was measured at 450 nm with a 
reference wavelength of 655 nm by microplate reader 
(Tecan Systems).
Immunohistochemical analysis of tumor tissues
Solid tumors from control and the various treated 
groups were fixed with 10% phosphate-buffered formalin, 
processed, and embedded in paraffin. The sections were 
cut and deparafinized in xylene, dehydrated in graded 
alcohol, and finally hydrated in water. Antigen retrieval 
was conducted by boiling the slide in 10 mmol/L sodium 
citrate (pH 6.0) for 30 min. Immunohistochemistry was 
conducted following the manufacturer’s instructions 
(Dako LSAB Kit). Briefly, endogenous peroxidases 
were quenched with 3% hydrogen peroxide. Nonspecific 
binding was blocked by incubation in the blocking 
reagent in the LSAB Kit (Dako) according to the 
manufacturer’s instructions. Sections were incubated 
overnight with primary antibodies as follows: anti-p65, 
anti-Ki-67, anti-VEGF, anti-Bcl-2 and anti-caspase3 
(each at 1:100 dilutions). The slides were subsequently 
washed several times in TBS with 0.1% Tween-20 and 
were incubated with biotinylated linker for 30 minutes, 
followed by incubation with streptavidin conjugate 
provided in the LSAB Kit according to the manufacturer’s 
instructions. Immunoreactive species were detected using 
3,3′-diaminobenzidine tetrahydrochloride as a substrate. 
The sections were counterstained with Gill’s hematoxylin 
and mounted under glass cover slips. Images were taken 
using an Olympus BX51 microscope (magnification, ×20). 
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Positive cells (brown) were quantitated using the Image-
Pro plus 6.0 software package (Media Cybernetics, Inc.). A 
total of five fields were examined and counted from three 
tumors of each treatment group. The values were initially 
subjected to one-way ANOVA and then later compared 
among groups using an unpaired Student’s t test, with p < 
0.05 considered to be significant.
Analysis of serum levels of IL-6 and TNF-α 
The serum levels of IL-6 and TNF-α were 
determined using ELISA kits R&D systems (Minneapolis, 
USA) as per manufacturer’s instructions. Blood collected 
from mice was incubated for 30 minutes at room 
temperature and then centrifuged at 1500 ×g at 4°C for 10 
min to collect the serum. Briefly 50 μL assay diluent was 
added to the wells of antibody coated microplates followed 
by 50 μL sample/Standard. The plates were allowed to 
incubate at room temperature for 2 hours. The contents 
of the well was aspirated and then washed with 1X wash 
buffer for 5 times. Mouse IL-6/ TNF-α antibody (100 μL) 
was added to all wells and allowed to incubate for 2 h at 
room temperature. The aspiration/washing was repeated 
and 100 μL of substrate solution added to each well, 
followed by incubation at room temperature for 30 min. 
Stop solution (100 μL) was added to each well, mixed and 
then optical density measured using a microplate reader 
set to 450 nm.
Statistical analysis
Data are expressed as the mean ± S.D. In all figures, 
vertical error bars denote the S.D. The significance of 
differences between groups was evaluated by Student’s 
t-test and one way analysis of variance, (ANOVA) test. 
A p value of less than 0.05 was considered statistically 
significant.
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